期刊文献+

抑制PAR4表达对肠癌细胞SW620药敏性的影响

下载PDF
导出
摘要 目的 探讨抑制PAR4表达对肠癌细胞SW620药敏性的影响.方法 采用MTT法测定SW620细胞、空载体转染细胞SW620/pcDNA3.1(+)和针对人PAR4的人工microRNA表达载体转染细胞SW620-ml、SW620-m2对肠癌临床常用化疗药物5-氟尿嘧啶和顺铂的IC50,分析抑制PAR4的表达对SW620细胞药物敏感性的影响.结果 与SW620和SW620/pcDNA3.1(+)两组对照细胞相比,PAR4表达受抑制的SW620-ml、 SW620-m2两组细胞对5-氟尿嘧啶的IC50均显著升高(p<0.01),对顺铂的IC50亦有明显升高(P<0.01,P<0.05).结论 抑制肠癌SW620细胞PAR4的表达将增加其对5-氟尿嘧啶和顺铂的耐受,提示以PAR4为靶点的肠癌联合药物治疗研究需要综合考虑用药的合理性. Objective To explore the effect of PAR4 inhibition on sensitivity to chemotherapeutic drugs of human colorectal carcinoma SW620 cells. Methods MTT method was used to determine the half-inhibition concentration ( IC50 ) to chemotherapeutic drugs that are commonly used in clinical treatment of colorectal cancer 5-Fu and DDP for human colorectal carcinoma SW620 cells, vector-alone transfected SW620 cells and PAR4- targeting artificial microRNA-expressing vector transfected SW620-ml and SW620-m2 cells. Results Compared with parental cell line SW620 and vector control SW620/pcDNA3.1 ( + ) cells, the SW620-m 1 and SW620-m2 cell line with inhibited PAR4 expression exhibited significantly increased IC50 for 5-Fu ( P〈0.01 ) and DDP ( P〈0.01, P〈0105 ) . Conclusions Inhibition of PAR4 expression in SW620 cells leads to the increase of drug resistance to 5-Fu and cisplatin, which suggests that reasonableness should be considered when conducting investigation on combination of PAR4- targeting therapy with other chemotherapeutic drugs for colorectal cancer treatment.
作者 韩娜 曹江
出处 《浙江临床医学》 2015年第10期1653-1655,共3页 Zhejiang Clinical Medical Journal
基金 国家自然科学基金(30271450,30672365)
关键词 PAR4 表达 抑制 肠癌 药敏 PAR4 Expression Inhibition Colorectal cancer Drug sensitivity
  • 相关文献

参考文献14

  • 1Prados J,Melguizo C,Ortiz R,et al.Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs. Anticancer Agents Med Chem,2013,13(8): 1204-1216.
  • 2Chung HHJang BI.A perspective: role of targeted therapy in colon cancer. KoreanJ Gastroenterol,2013,61(3): 128-135.
  • 3Audigier Y,Picault FX, Chaves-Almagro C,et al.G protein-coupled receptors in cancer: biochemical interactions and drug design. Prog Mol Biol Transl Sci,2013,115: 143-173.
  • 4Chung H,Hamza M,Oikonomopoulou K, et al. Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase- activated receptors. Biol Chem,2012,393(5): 413-420.
  • 5Filmore D.It' s a GPCtk world. Modem Drag Discovery,2004,7(11): 24-28.
  • 6Elste AP,Petersen I.Expression of proteinase-activated receptor 1-4(PAR 1-4)in human cancer.J Mol Histol,2010,4(41): 89-99.
  • 7Han N,Chu LS,Cao J.Construction and application of an artificial microR.NA expression vector for inhibiting PAR4. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(11): 1105-1107.
  • 8Hong L, Yang Z, Ma J, et al. Function of miRNA in contronllingdrug resistance of htunan cancers. Curr Drug Targets, 2013, 14(10): 1118-1127.
  • 9Chen Y,Tang Y,Guo C, et al. Nuclear receptors in the multigrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol, 2012, 83(8): 1112-1126.
  • 10Toton E, Ignatowicz E, Skrzeczkowska K, et al. Protein Kinase C g as a cancer Marker for anticancer therapy. Pharmacol Rep, 2011, 63(1): 19-29.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部